2-47403211-A-G

Variant names:

• chr2-47403211-A-G
• rs530071578
• NM_000251.3:c.20A>G

Variant summary

Our verdict is Uncertain significance. The variant received 0 ACMG points: 2P and 2B. PM2 BP4 BP6

The NM_000251.3(MSH2):​c.20A>G​(p.Glu7Gly) variant causes a missense change. The variant allele was found at a frequency of 0.000000691 in 1,447,378 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E7A) has been classified as Uncertain significance.

• Frequency:
  • Genomes: not found (cov: 33)
  • Exomes 𝑓: 6.9e-7 (0 hom.)
• Consequence: MSH2 NM_000251.3 missense
• Clinical Significance: Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:4 B:1
• Conservation: PhyloP100: 6.32
• Publications: 2 publications found

Genes affected

MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

MSH2 Gene-Disease associations (from GenCC):

• Lynch syndrome

  Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
• Lynch syndrome 1

  Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
• Muir-Torre syndrome

  Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
• mismatch repair cancer syndrome 1

  Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
• mismatch repair cancer syndrome 2

  Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
• ovarian cancer

  Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
• malignant pancreatic neoplasm

  Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
• prostate cancer

  Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
• rhabdomyosarcoma

  Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
• breast cancer

  Inheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
• hereditary breast carcinoma

  Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

ACMG classification

Our verdict: Uncertain_significance. The variant received 0 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• BP4: Computational evidence support a benign effect (MetaRNN=0.2939593).
• BP6: Variant 2-47403211-A-G is Benign according to our data. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481. Variant chr2-47403211-A-G is described in CliVar as Conflicting_classifications_of_pathogenicity. Clinvar id is 408481.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
MSH2	NM_000251.3	c.20A>G	p.Glu7Gly	missense_variant	Exon 1 of 16	ENST00000233146.7	NP_000242.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
MSH2	ENST00000233146.7	c.20A>G	p.Glu7Gly	missense_variant	Exon 1 of 16	1	NM_000251.3	ENSP00000233146.2

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD4 exome AF: 6.91e-7 AC: 1 AN: 1447378 Hom.: 0 Cov.: 31 AF XY: 0.00000139 AC XY: 1 AN XY: 718786

African (AFR) AF: 0.00 AC: 0 AN: 33328

American (AMR) AF: 0.00 AC: 0 AN: 42392

Ashkenazi Jewish (ASJ) AF: 0.00 AC: 0 AN: 25780

East Asian (EAS) AF: 0.00 AC: 0 AN: 39204

South Asian (SAS) AF: 0.00 AC: 0 AN: 83908

European-Finnish (FIN) AF: 0.00 AC: 0 AN: 50870

Middle Eastern (MID) AF: 0.00 AC: 0 AN: 5626

European-Non Finnish (NFE) AF: 9.04e-7 AC: 1 AN: 1106436

Other (OTH) AF: 0.00 AC: 0 AN: 59834

GnomAD4 genome Cov.: 33

ClinVar

Significance: Conflicting classifications of pathogenicity

Submissions summary: Uncertain:4 Benign:1

Revision: criteria provided, conflicting classifications

Submissions by phenotype

Hereditary cancer-predisposing syndrome Uncertain:1 Benign:1

Jul 29, 2021

Color Diagnostics, LLC DBA Color Health

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This missense variant replaces glutamic acid with glycine at codon 7 of the MSH2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -

Sep 02, 2022

Ambry Genetics

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

MSH2-related disorder Uncertain:1

Aug 26, 2024

PreventionGenetics, part of Exact Sciences

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

The MSH2 c.20A>G variant is predicted to result in the amino acid substitution p.Glu7Gly. To our knowledge, this variant has not been reported in individuals with MSH2-associated diseases in the literature or in a large population database, indicating this variant is rare. This variant is interpreted as a variant of uncertain significance by majority of the submitters in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/408481/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

not provided Uncertain:1

May 28, 2022

Quest Diagnostics Nichols Institute San Juan Capistrano

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The variant has not been reported in the published literature. It also has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -

Hereditary nonpolyposis colorectal neoplasms Uncertain:1

Sep 27, 2023

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant has not been reported in the literature in individuals affected with MSH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 408481). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 33357406) indicates that this missense variant is not expected to disrupt MSH2 function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 7 of the MSH2 protein (p.Glu7Gly). -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Benign	0.30
BayesDel_addAF	Pathogenic	0.19	D
BayesDel_noAF	Uncertain	0.030
CADD	Uncertain	25
DANN	Uncertain	1.0
DEOGEN2	Uncertain	0.44	T;.;.
Eigen	Benign	-0.025
Eigen_PC	Benign	0.16
FATHMM_MKL	Pathogenic	0.98	D
LIST_S2	Uncertain	0.86	D;D;D
M_CAP	Pathogenic	0.42	D
MetaRNN	Benign	0.29	T;T;T
MetaSVM	Uncertain	-0.027	T
MutationAssessor	Benign	1.8	L;.;.
PhyloP100		6.3
PrimateAI	Uncertain	0.54	T
PROVEAN	Benign	-1.6	N;.;N
REVEL	Uncertain	0.41
Sift	Uncertain	0.025	D;.;D
Sift4G	Benign	0.22	T;.;T
Polyphen		0.0	B;.;B
Vest4		0.39
MutPred		0.26		Loss of ubiquitination at K6 (P = 0.0675);Loss of ubiquitination at K6 (P = 0.0675);Loss of ubiquitination at K6 (P = 0.0675);
MVP		0.86
MPC		0.0064
ClinPred		0.95	D
GERP RS		4.3
PromoterAI		-0.068	Neutral
Varity_R		0.35
gMVP		0.38
Mutation Taster		=84/16	polymorphism

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.010		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Other links and lift over

dbSNP: rs530071578; hg19: chr2-47630350;